When the tumor size was increasing or the patient was developing metastasis, the serum levels of anti-IGFBP-2 antibodies were increased, suggesting a role for anti-IGFBP-2 antibodies in assessing response to therapy in lung cancer. Here, IGFBP2 is linked to lung cancer.